JP2019536429A - ポリオーマウイルスのための免疫療法 - Google Patents

ポリオーマウイルスのための免疫療法 Download PDF

Info

Publication number
JP2019536429A
JP2019536429A JP2019514037A JP2019514037A JP2019536429A JP 2019536429 A JP2019536429 A JP 2019536429A JP 2019514037 A JP2019514037 A JP 2019514037A JP 2019514037 A JP2019514037 A JP 2019514037A JP 2019536429 A JP2019536429 A JP 2019536429A
Authority
JP
Japan
Prior art keywords
epitopes
epitope
virus
polyomavirus
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019514037A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019536429A5 (https=
Inventor
カンナ，ラジーブ
ロビン アンバラティンガル トーマス，ジョージ
ロビン アンバラティンガル トーマス，ジョージ
アフテーブ，ブレイク，トル
Original Assignee
アタラ バイオセラピューティクス，インコーポレーテッド
アタラ バイオセラピューティクス，インコーポレーテッド
ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ
ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アタラ バイオセラピューティクス，インコーポレーテッド, アタラ バイオセラピューティクス，インコーポレーテッド, ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ, ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ filed Critical アタラ バイオセラピューティクス，インコーポレーテッド
Publication of JP2019536429A publication Critical patent/JP2019536429A/ja
Publication of JP2019536429A5 publication Critical patent/JP2019536429A5/ja
Priority to JP2023000505A priority Critical patent/JP7821133B2/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
JP2019514037A 2016-09-09 2017-09-08 ポリオーマウイルスのための免疫療法 Pending JP2019536429A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023000505A JP7821133B2 (ja) 2016-09-09 2023-01-05 ポリオーマウイルスのための免疫療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662385456P 2016-09-09 2016-09-09
US62/385,456 2016-09-09
PCT/US2017/050686 WO2018049165A1 (en) 2016-09-09 2017-09-08 Immunotherapy for polyomaviruses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023000505A Division JP7821133B2 (ja) 2016-09-09 2023-01-05 ポリオーマウイルスのための免疫療法

Publications (2)

Publication Number Publication Date
JP2019536429A true JP2019536429A (ja) 2019-12-19
JP2019536429A5 JP2019536429A5 (https=) 2020-10-22

Family

ID=61562223

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019514037A Pending JP2019536429A (ja) 2016-09-09 2017-09-08 ポリオーマウイルスのための免疫療法
JP2023000505A Active JP7821133B2 (ja) 2016-09-09 2023-01-05 ポリオーマウイルスのための免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023000505A Active JP7821133B2 (ja) 2016-09-09 2023-01-05 ポリオーマウイルスのための免疫療法

Country Status (14)

Country Link
US (1) US20200197439A1 (https=)
EP (1) EP3509632A4 (https=)
JP (2) JP2019536429A (https=)
KR (2) KR20240133760A (https=)
CN (1) CN109922830A (https=)
AU (2) AU2017322397A1 (https=)
BR (1) BR112019004102A2 (https=)
CA (1) CA3035906A1 (https=)
IL (1) IL265103B2 (https=)
MX (1) MX2019002566A (https=)
PH (1) PH12019500344A1 (https=)
RU (1) RU2019110269A (https=)
SG (1) SG11201901166QA (https=)
WO (1) WO2018049165A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3000183T3 (en) 2018-09-10 2025-02-27 Atara Biotherapeutics Inc Methods for expanding antigen-specific car-t cells, compositions and uses related thereto
CA3148391A1 (en) * 2019-07-24 2021-01-28 The Council Of The Queensland Institute Of Medical Research Immunotherapy for polyomaviruses
CN113278634B (zh) * 2020-11-16 2022-06-28 艾棣维欣(苏州)生物制药有限公司 一种预防和治疗默克尔细胞癌的新型疫苗

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008116468A2 (en) * 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105505870B (zh) * 2016-01-20 2017-07-25 深圳市中美康士生物科技有限公司 免疫细胞培养方法以及人工滋养细胞在免疫细胞培养中的用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008116468A2 (en) * 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"large T [Human polyomavirus 1]", DATABASE GENBANK [ONLINE], JPN6021043840, 7 August 2007 (2007-08-07), pages 75325, ISSN: 0004635048 *
"small t [Human polyomavirus 1]", DATABASE GENBANK [ONLINE], JPN6021043841, 7 August 2007 (2007-08-07), pages 75326, ISSN: 0004635047 *
"VP1 [Human polyomavirus 1]", DATABASE GENBANK [ONLINE], JPN6021043839, 26 January 2006 (2006-01-26), pages 53654, ISSN: 0004635049 *
CYTOTHERAPY, vol. 16, JPN6021043837, 2014, pages 1325 - 1335, ISSN: 0004867258 *
HUMAN IMMUNOLOGY, vol. 70, JPN6021043838, 2009, pages 722 - 728, ISSN: 0004867257 *
JOURNAL OF GENERAL VIROLOGY, vol. 87, JPN6021043836, 2006, pages 2951 - 2960, ISSN: 0004635052 *
JOURNAL OF VIROLOGY, vol. 79, no. 17, JPN6021043834, 2005, pages 11170 - 11178, ISSN: 0004635054 *
VIROLOGY, vol. 350, JPN6021043835, 2006, pages 128 - 136, ISSN: 0004635053 *

Also Published As

Publication number Publication date
CA3035906A1 (en) 2018-03-15
RU2019110269A (ru) 2020-10-09
PH12019500344A1 (en) 2020-01-20
IL265103B1 (en) 2024-02-01
MX2019002566A (es) 2019-12-05
WO2018049165A1 (en) 2018-03-15
CN109922830A (zh) 2019-06-21
IL265103A (https=) 2019-04-30
NZ751506A (en) 2023-09-29
JP2023040149A (ja) 2023-03-22
KR20190068529A (ko) 2019-06-18
KR20240133760A (ko) 2024-09-04
AU2017322397A1 (en) 2019-04-04
BR112019004102A2 (pt) 2019-05-28
IL265103B2 (en) 2024-06-01
US20200197439A1 (en) 2020-06-25
SG11201901166QA (en) 2019-03-28
KR102698554B1 (ko) 2024-08-23
EP3509632A1 (en) 2019-07-17
JP7821133B2 (ja) 2026-02-26
AU2024264673A1 (en) 2024-12-05
EP3509632A4 (en) 2021-02-17
RU2019110269A3 (https=) 2020-12-03

Similar Documents

Publication Publication Date Title
ES2328945T3 (es) Epitopos inmunogenos de linfocitos t colaboradores de antigenos tumorales humanos y metodos inmunoterapeuticos utilizando dichos epitopos.
JP7821133B2 (ja) ポリオーマウイルスのための免疫療法
US20110097312A1 (en) Anti-cancer vaccines
WO2014004385A2 (en) Anti-cancer vaccines
JP7270382B2 (ja) 免疫療法の方法
JP2025160241A (ja) ポリオーマウイルスのための免疫療法
WO2008007711A1 (en) Sart3-derived peptide useful in cancer vaccine therapy for hla-a3 supertype allele-positive prostate cancer patient
JP5065273B2 (ja) Ｈｌａ−ａ２４分子結合性ｋｉｆ由来ペプチド
CA2536654A1 (en) Anti-cancer vaccines
EP2270144B1 (en) Partial peptide of survivin presented on mhc class ii molecule and use thereof
JP2019520840A (ja) マルチウイルス特異的ｔ細胞免疫療法
US20250057881A1 (en) Compositions and methods for use of recombinant t cell receptors against claudin 6
NL2034657B1 (en) RCN1-derived TEIPP neoantigens and uses thereof
JP6918333B2 (ja) 細胞性免疫に認識されるペプチド、及びそれを利用した医薬薬剤
WO2024194498A2 (en) Cross reactive microbial peptide cancer vaccine and t cell receptors reactive thereto
HK40005722A (en) Immunotherapy for polyomaviruses
CN120857941A (zh) 经验证的hpv16衍生的刺激肽
JP2021526826A (ja) ウイルス検出アッセイ
NZ751506B2 (en) Immunotherapy for polyomaviruses

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20191030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220203

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220425

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220906

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20221228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230105

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230106

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230131

C27A Decision to dismiss

Free format text: JAPANESE INTERMEDIATE CODE: C2711

Effective date: 20230322

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20230411